Genitope's (GTOP) shares sank 4.3% to $2.46 after the company discussed interim data on its MyVax personalized immunotherapy for previously untreated follicular lymphoma. According to a regulatory filing and a conference call, as of June 15, more than half of the patients in a late-phase MyVax clinical trial, or 158 of 287 patients, got worse.


Shares of Cephalon (CEPH) were up 1.5% to $57.93 after investment bank Morgan Stanley initiated coverage of the stock.

Novavax (NVAX) rose after the company named Jeffrey Church its new chief financial officer. Church was most recently CFO at GenVec. Novavax shares were up 4.8% to $3.27.


Micromet (MITI) , down 6.3% to $2.53, Illumina (ILMN) , falling 2.9% to $31.95, Valera Pharmaceuticals (VLRX) , 6.7% lower to $5.99, Tapestry Pharmaceuticals (TPPH) , down 3.2% to $2.73, and GlaxoSmithKline (GSK) , whose shares fell 1.1% to $55.02.

ImClone Systems (IMCL) gained 2.9% to $29.83, Affymetrix (AFFX) was up 5.1% to $22.06, Amgen (AMGN) rose 0.8% to $67.12, Dendreon (DNDN) advanced 2.6% to $4.38 and Pharmion (PHRM) was up 7.9% to $18.09.